Search clinical trials for: MK0869, aprepitant

Total 329 results

Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

Breast Neoplasms | Nausea | Vomiting
Merck Sharp & Dohme LLC

Completed

2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)

Postoperative Nausea and Vomiting
Merck Sharp & Dohme LLC

Completed

2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)

Postoperative Nausea and Vomiting
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)

Chemotherapy Induced Nausea and Vomiting
Merck Sharp & Dohme LLC

Completed

Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)

Chemotherapy-Induced Nausea and Vomiting (CINV)
Merck Sharp & Dohme LLC

Completed

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)

Nausea | Vomiting
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

Breast Neoplasms | Nausea | Vomiting
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Terminated

A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)

Relapsing-Remitting Multiple Sclerosis
Merck Sharp & Dohme LLC

Completed

A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)

Pulmonary Disease, Chronic Obstructive
Merck Sharp & Dohme LLC

Terminated

A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011)

Osteoarthritis

United States, Chile, Colombia, Mexico, Poland
Merck Sharp & Dohme LLC

Terminated

MK0767 in Type 2 Diabetes (0767-012)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

Study A - MK0767 Monotherapy Study

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)

Chemotherapy-Induced Nausea and Vomiting
Merck Sharp & Dohme LLC

Completed

Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)

Post-Menopausal Osteoporosis
Merck Sharp & Dohme LLC

Completed

MK0686 in Postsurgery Dental Pain (0686-002)

Pain, Postoperative
Merck Sharp & Dohme LLC

Terminated

MK0767 and Sulfonylurea Combination Study (0767-027)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Terminated

Dyslipidemia in Type 2 Diabetes (0767-034)

Dyslipidemia | Diabetes Mellitus, Type II
Merck Sharp & Dohme LLC

Terminated

A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005)

Neuralgia, Postherpetic
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)

Rheumatoid Arthritis
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate the Efficacy of MK0719 in the Prevention of Postoperative Dental Pain (0719-002)

Pain, Postoperative
Merck Sharp & Dohme LLC

Completed

A Study of MK0359 in Patients With Chronic Asthma (0359-013)

Asthma
Merck Sharp & Dohme LLC

Terminated

Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004)

Neuralgia, Postherpetic
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Safety and Efficacy of an Investigational Drug (MK-686) in Patients With Osteoarthritis (0686-006)

Osteoarthritis
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)

Post-operative Nausea | Post-operative Vomiting
LEO Pharma

Completed

Topical Aprepitant in Prurigo Patients (iTAPP)

Pruritus

Germany
The Affiliated Hospital of Qingdao University

Not yet recruiting

Comparative Pharmacokinetic Study of Aprepitant Injection in Humans

Healthy
Merck Sharp & Dohme LLC

Withdrawn

A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

Prostate Cancer
Merck Sharp & Dohme LLC

Completed

Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)

Alzheimer's Disease
The Hospital for Sick Children

Completed

Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers

Chemotherapy-induced Nausea and Vomiting

Canada
Merck Sharp & Dohme LLC

Completed

Re-examination Study of EMEND (Aprepitant) (MK-0869-184)

Chemotherapy-induced Nausea and Vomiting
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822)

Osteoporosis
University of Virginia
National Institute on Drug Abuse (NIDA)

Completed

Medications Development for the Treatment of Cannabis Related Disorders (MTC)

Cannabis Dependence | Nicotine Dependence | Marijuana Dependence | Cannabis Abuse | Nicotine Withdrawal

United States
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Odanacatib (0822-059)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)

Paranoid Schizophrenia
University Hospital, Rouen

Completed

Effects of Substance P Antagonists on Adrenal Secretion (APHOS)

Healthy Volunteers

France
Merck Sharp & Dohme LLC

Completed

A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)

Osteoporosis
Sharon Walsh
National Institute on Drug Abuse (NIDA); Merck Sharp & Dohme LLC

Completed

Aprepitant Effects on Oxycodone Response

Narcotic Abuse

United States
Merck Sharp & Dohme LLC

Terminated

MK0767 and Metformin Combination Study (0767-028)

Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Terminated

Dose-Range Finding Study for MK0893 (0893-008)

Diabetes Mellitus, Type 2

3

Subscribe